Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.

Juliá EP, Mandó P, Rizzo MM, Cueto GR, Tsou F, Luca R, Pupareli C, Bravo AI, Astorino W, Mordoh J, Martín C, Levy EM.

Cancer Immunol Immunother. 2019 Sep 12. doi: 10.1007/s00262-019-02391-z. [Epub ahead of print]

PMID:
31515670
2.

Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.

Mac Keon S, Bentivegna S, Levy EM, Marks MS, Mantegazza AR, Wainstok R, Mordoh J.

Vaccine. 2019 Aug 14;37(35):4947-4955. doi: 10.1016/j.vaccine.2019.07.018. Epub 2019 Jul 13.

3.

Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants.

Pampena MB, Cartar HC, Cueto GR, Levy EM, Blanco PA, Barrio MM, Mordoh J.

Front Immunol. 2018 Nov 2;9:2531. doi: 10.3389/fimmu.2018.02531. eCollection 2018.

4.

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.

Juliá EP, Amante A, Pampena MB, Mordoh J, Levy EM.

Front Immunol. 2018 Sep 20;9:2140. doi: 10.3389/fimmu.2018.02140. eCollection 2018.

5.

High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients.

Mandó P, Rizzo M, Roberti MP, Juliá EP, Pampena MB, Pérez de la Puente C, Loza CM, Ponce C, Nadal J, Coló FA, Mordoh J, Levy EM.

Onco Targets Ther. 2018 May 17;11:2901-2910. doi: 10.2147/OTT.S160911. eCollection 2018.

6.

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.

Aris M, Bravo AI, Pampena MB, Blanco PA, Carri I, Koile D, Yankilevich P, Levy EM, Barrio MM, Mordoh J.

Front Immunol. 2018 May 3;9:955. doi: 10.3389/fimmu.2018.00955. eCollection 2018.

7.

Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia.

Ruiz MS, Sanchez MB, Gutiérrez L, Koile D, Yankilevich P, Mosqueira C, Cranco S, Custidiano MDR, Freitas J, Foncuberta C, Moiraghi B, Pavlovsky C, Pérez MA, Ventriglia V, Ávalos JS, Mordoh J, Larripa I, Bianchini M.

Oncotarget. 2018 Apr 17;9(29):20255-20264. doi: 10.18632/oncotarget.24749. eCollection 2018 Apr 17.

8.

Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release.

Pampena MB, Barrio MM, Juliá EP, Blanco PA, von Euw EM, Mordoh J, Levy EM.

Front Immunol. 2017 Oct 23;8:1342. doi: 10.3389/fimmu.2017.01342. eCollection 2017.

9.

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma.

Aris M, Mordoh J, Barrio MM.

Front Immunol. 2017 Aug 25;8:1024. doi: 10.3389/fimmu.2017.01024. eCollection 2017. Review.

10.

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study.

Mordoh J, Pampena MB, Aris M, Blanco PA, Lombardo M, von Euw EM, Mac Keon S, Yépez Crow M, Bravo AI, O'Connor JM, Orlando AG, Ramello F, Levy EM, Barrio MM.

Front Immunol. 2017 May 31;8:625. doi: 10.3389/fimmu.2017.00625. eCollection 2017.

11.

Metallothionein 1G promotes the differentiation of HT-29 human colorectal cancer cells.

Arriaga JM, Bravo AI, Mordoh J, Bianchini M.

Oncol Rep. 2017 May;37(5):2633-2651. doi: 10.3892/or.2017.5547. Epub 2017 Apr 3.

12.

In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells.

Madorsky Rowdo FP, Barón A, von Euw EM, Mordoh J.

Oncol Rep. 2017 Mar;37(3):1367-1378. doi: 10.3892/or.2017.5363. Epub 2017 Jan 13.

13.

Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators.

Ruiz MS, Medina M, Tapia I, Mordoh J, Cross NC, Larripa I, Bianchini M.

Leukemia. 2016 Nov;30(11):2258-2260. doi: 10.1038/leu.2016.197. Epub 2016 Jul 25. No abstract available.

14.

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.

Rocca YS, Roberti MP, Juliá EP, Pampena MB, Bruno L, Rivero S, Huertas E, Sánchez Loria F, Pairola A, Caignard A, Mordoh J, Levy EM.

Front Immunol. 2016 Oct 10;7:413. eCollection 2016.

15.

Editorial: "Cancer Immunotherapy: Lights and Shadows".

Barrio MM, Levy EM, Mordoh J.

Front Immunol. 2015 Jul 7;6:350. doi: 10.3389/fimmu.2015.00350. eCollection 2015. No abstract available.

16.

Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine.

Pizzurro GA, Tapia IJ, Sganga L, Podhajcer OL, Mordoh J, Barrio MM.

Cancer Immunol Immunother. 2015 Nov;64(11):1393-406. doi: 10.1007/s00262-015-1743-z. Epub 2015 Jul 22.

PMID:
26197849
17.

Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report.

Aris M, Bravo AI, Barrio MM, Mordoh J.

Front Immunol. 2015 Mar 30;6:144. doi: 10.3389/fimmu.2015.00144. eCollection 2015.

18.

Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.

Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J.

Front Immunol. 2015 Mar 26;6:127. doi: 10.3389/fimmu.2015.00127. eCollection 2015. Review.

19.

Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.

Roberti MP, Juliá EP, Rocca YS, Amat M, Bravo AI, Loza J, Coló F, Loza CM, Fabiano V, Maino M, Podhorzer A, Fainboim L, Barrio MM, Mordoh J, Levy EM.

Eur J Immunol. 2015 May;45(5):1560-9. doi: 10.1002/eji.201445353. Epub 2015 Apr 7.

20.

Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy.

Arriaga JM, Greco A, Mordoh J, Bianchini M.

Mol Cancer Ther. 2014 May;13(5):1369-81. doi: 10.1158/1535-7163.MCT-13-0944. Epub 2014 Mar 14.

21.

Development of a novel methodology for cryopreservation of melanoma cells applied to CSF470 therapeutic vaccine.

Tapia IJ, Aris M, Arriaga JM, Blanco PA, Mazzobre F, Vega J, Mordoh J, Barrio MM.

Cryobiology. 2013 Oct;67(2):163-9. doi: 10.1016/j.cryobiol.2013.06.007. Epub 2013 Jul 9.

PMID:
23850827
22.

A word of caution: do not wake sleeping dogs; micrometastases of melanoma suddenly grew after progesterone treatment.

Mordoh J, Tapia IJ, Barrio MM.

BMC Cancer. 2013 Mar 20;13:132. doi: 10.1186/1471-2407-13-132.

23.

Biological role of NK cells and immunotherapeutic approaches in breast cancer.

Roberti MP, Mordoh J, Levy EM.

Front Immunol. 2012 Dec 12;3:375. doi: 10.3389/fimmu.2012.00375. eCollection 2012.

24.

Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors.

Campisano S, Mac Keon S, Gazzaniga S, Ruiz MS, Traian MD, Mordoh J, Wainstok R.

Vaccine. 2013 Jan 2;31(2):354-61. doi: 10.1016/j.vaccine.2012.10.114. Epub 2012 Nov 10.

PMID:
23146677
25.

IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.

Roberti MP, Rocca YS, Amat M, Pampena MB, Loza J, Coló F, Fabiano V, Loza CM, Arriaga JM, Bianchini M, Barrio MM, Bravo AI, Domenichini E, Chacón R, Mordoh J, Levy EM.

Breast Cancer Res Treat. 2012 Dec;136(3):659-71. doi: 10.1007/s10549-012-2287-y. Epub 2012 Oct 14.

PMID:
23065032
26.

Lessons from cancer immunoediting in cutaneous melanoma.

Aris M, Barrio MM, Mordoh J.

Clin Dev Immunol. 2012;2012:192719. doi: 10.1155/2012/192719. Epub 2012 Aug 14. Review.

27.

Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice.

Roberti MP, Arriaga JM, Bianchini M, Quintá HR, Bravo AI, Levy EM, Mordoh J, Barrio MM.

Cancer Biol Ther. 2012 Sep;13(11):1123-40. doi: 10.4161/cbt.21187. Epub 2012 Jul 24.

28.

Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients.

Rocca YS, Roberti MP, Arriaga JM, Amat M, Bruno L, Pampena MB, Huertas E, Loria FS, Pairola A, Bianchini M, Mordoh J, Levy EM.

Innate Immun. 2013 Feb;19(1):76-85. doi: 10.1177/1753425912453187. Epub 2012 Jul 10.

PMID:
22781631
29.

Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells.

Barrio MM, Abes R, Colombo M, Pizzurro G, Boix C, Roberti MP, Gélizé E, Rodriguez-Zubieta M, Mordoh J, Teillaud JL.

PLoS One. 2012;7(7):e40311. doi: 10.1371/journal.pone.0040311. Epub 2012 Jul 2.

30.

High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function.

Pizzurro GA, Madorsky Rowdo FP, Pujol-Lereis LM, Quesada-Allué LA, Copati AM, Roberti MP, Teillaud JL, Levy EM, Barrio MM, Mordoh J.

Cancer Immunol Immunother. 2013 Jan;62(1):3-15. doi: 10.1007/s00262-012-1295-4. Epub 2012 Jun 22.

PMID:
22722447
31.

Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities.

Madorsky-Rowdo FP, Lacreu ML, Mordoh J.

Front Immunol. 2012 May 4;3:103. doi: 10.3389/fimmu.2012.00103. eCollection 2012.

32.

Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer.

Arriaga JM, Bravo IA, Bruno L, Morales Bayo S, Hannois A, Sanchez Loria F, Pairola F, Huertas E, Roberti MP, Rocca YS, Aris M, Barrio MM, Baffa Trasci S, Levy EM, Mordoh J, Bianchini M.

Hum Pathol. 2012 Oct;43(10):1695-703. doi: 10.1016/j.humpath.2011.12.014. Epub 2012 Apr 17.

PMID:
22516242
33.

MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro.

Aris M, Zubieta MR, Colombo M, Arriaga JM, Bianchini M, Alperovich M, Bravo AI, Barrio MM, Mordoh J.

J Invest Dermatol. 2012 Feb;132(2):365-74. doi: 10.1038/jid.2011.312. Epub 2011 Oct 13.

34.

Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival.

Arriaga JM, Levy EM, Bravo AI, Bayo SM, Amat M, Aris M, Hannois A, Bruno L, Roberti MP, Loria FS, Pairola A, Huertas E, Mordoh J, Bianchini M.

Hum Pathol. 2012 Feb;43(2):197-208. doi: 10.1016/j.humpath.2011.04.015. Epub 2011 Aug 4.

PMID:
21820154
35.

Natural killer cells in human cancer: from biological functions to clinical applications.

Levy EM, Roberti MP, Mordoh J.

J Biomed Biotechnol. 2011;2011:676198. doi: 10.1155/2011/676198. Epub 2011 Apr 26. Review.

36.

Glycoproteomic characterization of carriers of the CD15/Lewisx epitope on Hodgkin's Reed-Sternberg cells.

Powlesland AS, Barrio MM, Mordoh J, Hitchen PG, Dell A, Drickamer K, Taylor ME.

BMC Biochem. 2011 Mar 24;12:13. doi: 10.1186/1471-2091-12-13.

37.

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.

Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, Mordoh J, Levy EM.

Breast Cancer Res Treat. 2011 Nov;130(2):465-75. doi: 10.1007/s10549-011-1360-2. Epub 2011 Feb 10.

PMID:
21308409
38.

Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue.

Mac Keon S, Gazzaniga S, Mallerman J, Bravo AI, Mordoh J, Wainstok R.

Vaccine. 2010 Nov 29;28(51):8162-8. doi: 10.1016/j.vaccine.2010.09.095. Epub 2010 Oct 27.

PMID:
20937314
39.

Targeted glycoproteomic identification of cancer cell glycosylation.

Powlesland AS, Hitchen PG, Parry S, Graham SA, Barrio MM, Elola MT, Mordoh J, Dell A, Drickamer K, Taylor ME.

Glycobiology. 2009 Aug;19(8):899-909. doi: 10.1093/glycob/cwp065. Epub 2009 May 11.

40.

Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.

Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, Morales SB, González M, Mordoh J, Bianchini M.

Innate Immun. 2009 Apr;15(2):91-100. doi: 10.1177/1753425908101404.

PMID:
19318419
41.

Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.

Fuertes MB, Girart MV, Molinero LL, Domaica CI, Rossi LE, Barrio MM, Mordoh J, Rabinovich GA, Zwirner NW.

J Immunol. 2008 Apr 1;180(7):4606-14.

42.

Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer.

Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C, Valvassori L, Mordoh J.

Int J Oncol. 2008 Mar;32(3):633-41.

PMID:
18292941
43.

GABABR1 (G1465A) gene variation and temporal lobe epilepsy controversy: new evidence.

Kauffman MA, Levy EM, Consalvo D, Mordoh J, Kochen S.

Seizure. 2008 Sep;17(6):567-71. doi: 10.1016/j.seizure.2007.12.006. Epub 2008 Feb 5.

44.

A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.

von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I, Lantz O, Vellice A, Kohan A, Chacón M, Yee C, Wainstok R, Mordoh J.

J Transl Med. 2008 Jan 25;6:6. doi: 10.1186/1479-5876-6-6.

45.

Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft.

Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J, Wainstok R.

J Invest Dermatol. 2007 Aug;127(8):2031-41. Epub 2007 Apr 26.

46.
47.

Sorting nexin 1 down-regulation promotes colon tumorigenesis.

Nguyen LN, Holdren MS, Nguyen AP, Furuya MH, Bianchini M, Levy E, Mordoh J, Liu A, Guncay GD, Campbell JS, Parks WT.

Clin Cancer Res. 2006 Dec 1;12(23):6952-9.

48.

Lewis x antigen mediates adhesion of human breast carcinoma cells to activated endothelium. Possible involvement of the endothelial scavenger receptor C-type lectin.

Elola MT, Capurro MI, Barrio MM, Coombs PJ, Taylor ME, Drickamer K, Mordoh J.

Breast Cancer Res Treat. 2007 Jan;101(2):161-74. Epub 2006 Jul 19.

49.

A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients.

Barrio MM, de Motta PT, Kaplan J, von Euw EM, Bravo AI, Chacón RD, Mordoh J.

J Immunother. 2006 Jul-Aug;29(4):444-54.

PMID:
16799340
50.

Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa.

Bianchini M, Levy E, Zucchini C, Pinski V, Macagno C, De Sanctis P, Valvassori L, Carinci P, Mordoh J.

Int J Oncol. 2006 Jul;29(1):83-94.

PMID:
16773188

Supplemental Content

Loading ...
Support Center